RajivAgarwal United States

Upload Picture

First Name

Rajiv

Last Name

Agarwal

Institution

Country.

United States

Time	Session

2:15 p.m. 3:45 p.m.	HIT! High Impact Clinical Trials – What and Why AndreaViecelli Chair andrea.viecelli@health.qld.gov.auUniversity of QueenslandAustralia Combination Effect of Finerenone and Empagliflozin in Participants With Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint Study (CONFIDENCE)—Baseline Characteristic RajivAgarwal Oral Abstract Presenter United States Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial KatherineTuttle Oral Abstract Presenter University of Washington School of Medicine, Division of NephrologyUnited States Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis BradRovin Oral Abstract Presenter The Ohio State UniversityUnited States Auditorium Brahmkamal Hall

Time

Session

2:15 p.m.

3:45 p.m.

HIT! High Impact Clinical Trials – What and Why

AndreaViecelli Chair andrea.viecelli@health.qld.gov.auUniversity of QueenslandAustralia

Combination Effect of Finerenone and Empagliflozin in Participants With Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint Study (CONFIDENCE)—Baseline Characteristic

RajivAgarwal Oral Abstract Presenter United States
Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial

KatherineTuttle Oral Abstract Presenter University of Washington School of Medicine, Division of NephrologyUnited States
Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis

BradRovin Oral Abstract Presenter The Ohio State UniversityUnited States

Auditorium Brahmkamal Hall